- Research article
- Open Access
Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes – a retrospective cohort study
© Ugale et al.; licensee BioMed Central Ltd. 2014
Received: 14 April 2014
Accepted: 14 August 2014
Published: 22 August 2014
Remission of diabetes is seen in more than 60% of patients after bariatric surgery. There is extensive variability in the remission rates between different surgical procedures. We analyzed our database and aimed to develop an easy scoring system to predict the probability of diabetes remission after two surgical procedures i.e. Ileal Interposition coupled with Sleeve Gastrectomy (IISG) or Diverted Sleeve Gastrectomy (IIDSG).
In this retrospective study, we analyzed records pertaining to patients who underwent IISG (n = 46) and IIDSG (n = 29). The primary outcome measure was diabetes remission (A1c <6.5% and not requiring hypoglycemic drugs). We identified seven preoperative clinical variables (age, duration of diabetes, body mass index, micro and macrovascular complications, use of insulin and stimulated C-peptide) based on our previous reports to be included in the diabetes remission score (DRS). The DRS score (7 – 14) was compared between the patients with and without remission in both the surgery groups.
Mean DRS in patients who underwent IISG was 9.2 ± 1.4. Twenty one (46%) had a remission in diabetes. DRS was significantly lower in patients with remission than patients without remission (8.1 ± 0.8 versus 10.2 ± 0.9, p < 0.0001). Mean DRS in patients who underwent IIDSG was 10.4 ± 1.3. Twenty one (72%) had a remission in diabetes. DRS was significantly lower in patients with remission than patients without remission (9.7 ± 0.8 versus 12.0 ± 0.5, p < 0.0001). Patients with a DRS ≥ 10 in IISG group and more than 12 in IIDSG group did not get into remission.
Preoperative DRS can be a useful tool to select the type of surgical procedure and to predict the postoperative diabetes remission.
Bariatric surgery in patients with type 2 diabetes is known to produce remission in a majority of cases. The improvement is not limited to diabetes alone and includes hypertension, dyslipidemia and obstructive sleep apnea as well. The magnitude and onset of this improvement outweighs the weight loss leading to the concept of ‘metabolic surgery’ rather than bariatric surgery . The observed metabolic benefits lead to the extension of this concept to non obese patients also [2-5]. Bariatric surgical procedures are primarily divided into restrictive and malabsorptive types. The most common surgical procedures are sleeve gastrectomy (SG), gastric banding, Roux-en-Y-Gastric Bypass (RYGB) and Jejuno-Ileal Bypass (JIB). The observed remission in diabetes after these surgeries is reported to range between 45-95% .
The standard procedures have been modified to achieve maximum remission with minimal long term complications. The modified surgical techniques are Ileal Interposition (II), Diverted Sleeve Gastrectomy (DSG), Sleeve Gastrectomy with Duodeno-jejunal Bypass (SG + DJB), Mini-Gastric Bypass (MGB) and Single Anastomosis Duodeno-Ileal (SADI) procedure . The results are often incomparable between procedures due to the differences involved in patients and the spectrum of diabetes. The proposed predictive factors for remission and other outcomes includes age, diabetes duration, insulin reserve& requirement, body mass index (BMI), ethnicity and number of preoperative medications required to manage blood glucose [7-12]. We observed a significant variability in the remission rates using IISG and IIDSG as reported previously [13-17]. A good predictive model is essential in helping the patients and clinicians to decide about the probability of remission based on preoperative criteria. We developed a novel scoring system known as Diabetes Remission Score (DRS) based on the previous database. Our intention is to develop a simple, effective and useful method to help the surgical teams in predicting the diabetes remission rates postoperatively.
The present study is a retrospective analysis of all the patients with poorly controlled type 2 diabetes mellitus (T2DM), who were subjected to the laparoscopic procedures of IISG or IIDSG at Kirloskar Hospital, Hyderabad, India. IISG was started in February 2008 and IIDSG was started in March 2010 and the study was duly approved by the hospital’s ethics committee (Institutional Review Board, Kirloskar Hospital, Hyderabad) and registered (NCT00834626). Informed consent was obtained from all patients participating in the study. Study participants were explained specifically about the benefits pertinent to nonobese subjects and the potential risks involved. The patient selection criteria and surgical techniques have been described in detail previously (13 – 17). Briefly, we included patients having T2DM of more than 1 year duration (>5 years duration for IIDSG), aged between 25 and 70 years, poor glycemic control with HbA1C > 7% on the optimum dosage of insulin ± oral hypoglycemic agents (OHA), stable weight, BMI ≥20 kg/m2 (>18.5 kg/m2 for IIDSG) and stimulated C-peptide level >1.5 ng/ml. The decision of mode of surgery (IISG or IIDSG) was taken by the surgical team in consultation with the endocrinologist and the patient’s preference. The study is a retrospective analysis of the patients profile precluding the possibility of random allocation into each group. We excluded patients with type 1 diabetes mellitus, undetectable fasting C-peptide, ketoacidosis in past 6 months, pregnancy and coexisting severe hepatic, pulmonary and psychiatric diseases.
Post operatively each participant was followed up at 1, 3, 6 ,9 and 12 months in the 1st year and every 6 months thereafter. They were subjected to clinical and biochemical assessment. HbA1C <6.5% (without requiring any medication for diabetes control) was defined as the criterion for remission in diabetes. Our study protocol was started in 2008 and the ADA defined diabetes remission into partial and complete in 2009 . Hence, our definition is similar to that of partial remission given by the ADA.
Statistical analysis & scoring system
Diabetes Remission Score Calculator
30 – 60
< 30 or >60
Body Mass Index (kg/m 2 )
Duration of T2DM (yr)
Preoperative Insulin use
Stimulated C-peptide (ng/mL)
Comparison between 2 groups regarding the clinical profile and complications
IISG group n = 46
IIDSG group n = 29
29 : 17
20 : 9
Duration of insulin use
Daily Insulin dose
Daily Insulin dose
Comparison between 2 groups regarding the surgical procedure and complications
IISG group n = 46
IIDSG group n = 29
Duration of follow up
Nausea - 12
Nausea – 6
Long term complications
B12 deficiency – 3
Comparison between the groups according to their body mass index
IISG group (N = 46)
IIDSG group (N = 29)
Number of Patients
Remission of DM
BMI at end point
Δ Body weight
Mean DRS in patients who underwent IIDSG (n = 29) was 10.4 ± 1.3 (Range: 8–14, significantly higher than II + SG group, p = 0.0004). Twenty one (72%) had a remission in diabetes. DRS was significantly lower in patients with remission than patients without remission (9.7 ± 0.8 versus 12.0 ± 0.5, p < 0.0001). All the patients with DRS 8–10 achieved remission, while 55% patients with DRS 11 had diabetes remission. There was no remission in diabetes in patients with baseline DRS ≥ 12.
Patients with DRS ≥ 10 in IISG group and DRS ≥ 12 in IIDSG group did not get into remission. DRS was not significantly different (p = 0.1468) in patients without remission in IISG (10.2 ± 0.9) versus patients with remission in IIDSG (9.7 ± 0.8). In patients with IIDSG, intraoperative complications were observed in 4 patients. One patient had a dusky duodenal stump leading to application of the drain. Another patient had a suture-passer tip breakage into the abdominal wall which was extricated by C arm. A 2 cm opening at the gastric antrum in another patient was closed in 3–0 PDS because of faulty stapling and the last patient had ileal perforation managed by exploratory laparotomy and closure. At 3 months postoperative follow up, none of these patients had any complications with regard to the intraoperative and immediate postoperative events.
Our study focuses on the development of a novel score (DRS) preoperatively in predicting diabetes remission following IISG or IIDSG. DRS was derived from the variable factors predicting the remission in diabetes. Our previous studies on IISG have demonstrated duration of diabetes, BMI and stimulated C-peptide response as baseline parameters of response [14,15]. Previous studies of RYGB reported that old age, longer duration of diabetes, lower C-peptide level, and lower BMI reduce the likelihood of response to surgery [7,20,21]. In type 2 diabetes patients with duration of diabetes < 5 years, a resolution of the disease was obtained in 95%, whereas the rate of resolution was only 75% and 54% in those who had type 2 diabetes for 6–10 or >10 years . Scopinaro et al. has shown that metabolic surgery is less effective in individuals with lower BMI [22,23]. Insulin resistance is a major contributing factor for diabetes in patients with high BMI, whereas beta cell dysfunction predominates in the normal weight individuals. Hence, the benefits of metabolic surgery are observed more in obese individuals when compared to nonobese patients. Our data also showed similar results in both the groups as shown in Table 4. IIDSG gives augmented stimulus to the enteroinsular hormonal axis leading to better resolution of diabetes. The baseline body weight and the amount of excess body weight lost determine the benefit rates in diabetes resolution. Previous reports suggest that diabetes remission is seen in 60% of patients with restrictive procedures and up to 80 – 90% in combined (restrictive and malabsorptive) procedures [6,23]. Advanced age is an important consideration for patient selection also, because of the augmented risks with surgery and weight loss [24,25].
DRS was significantly lower in patients with remission than patients without remission. This demonstrates that patients with lower baseline DRS have better remission rates and patients with DRS of 7–8 should only be subjected to IISG. Our data demonstrate that IIDSG may be taken up for patients with a DRS up to 11. Additionally DRS was not significantly different (p = 0.1468) in patients without remission in IISG (10.2 ± 0.9) versus patients with remission in IIDSG (9.7 ± 0.8). This indirectly suggests that IIDSG instead of IISG would have helped them in achieving remission.
IIDSG is more beneficial over the conventional IISG procedure due to the following points. The IIDSG excludes the duodenum, leading to attenuated release of Rubino’s factor (anti-incretin factor, which promotes insulin resistance) and Gastric Inhibitory Polypeptide (GIP) . Disruption or attenuation of GIP action is associated with decreased glucagon release, diminished weight gain, resistance to diet-induced obesity, and improved insulin sensitivity in preclinical studies [27-30], whereas genetic variation within the human Gastric Inhibitory Polypeptide Receptor (GIPR) gene is linked to control of postprandial glucose and body weight [31,32]. Exclusion of duodenum also leads to abolition of hedonic (pleasure) value of food, resulting in lesser indulgence in feeding . In comparison to IISG, the interposed ileal segment is shifted more proximally in IIDSG, leading to augmented glucagon like peptide (GLP-1) hormone secretion [16,17]. Our surgical technique has no risk of malabsorptive complications as the procedure does not involve removal of either intestinal digestive or absorptive surface. The previous published long term follow up studies using this technique also did not report any malabsorptive complications. Iron malabsorption is theoretically possible due to lack of gastric intrinsic factor after the surgery. However, we prescribed supplemental iron to all patients postoperatively preventing this complication.
The surgical technique used in this study is designed essentially for diabetes control and utilizes both the foregut and hindgut mechanisms . The SG component restricts calorie intake and reduces ghrelin ; it also speeds up gastric transit of food, reaching the ileal segment faster. The GLP-1 response is defective in T2DM leading to diminished first phase of insulin secretion . The ileal interposition helps in the rapid stimulation of ileal segment by ingested food leading to augmented GLP-1 secretion [13-15]. GLP-1 also influences glucose metabolism by inhibiting glucagon secretion, decreasing hepatic gluconeogenesis, delaying gastric emptying, promoting satiety, suppressing appetite, and stimulating glycogenesis [37-43].
We propose a baseline assessment of DRS as a possible predictor of remission in diabetes following IISG or IIDSG. The DRS may be divided into 3 grades as grade 1 (mild, DRS 7–8), grade 2 (moderate, 9–11) and grade 3 (severe, DRS 12–14). Higher scores indicate a diminished chance of achieving remission in a given patient. The advantages of DRS include an easy clinically relevant score, combining multiple factors affecting the diabetes and give an objective measure for comparison between the procedures. Our study has certain limitations. The study analysis and the development of DRS were based on retrospective observational analysis of the data. The DRS score was developed based on the data from sleeve gastrectomy and ileal interposition. Hence, DRS may not be useful for predicting remission of other bariatric or metabolic procedures. The status of obesity alone as a determinant of metabolic surgery is incorrect due to the identification of a phenotype called metabolically obese and normal weight individuals . This also limits the wide application of this scoring system prior to the surgery. The study was inadequately powered to give a definite conclusion due to limited number of the patients and mixed population in each group. Moreover, our data from a single center may not represent the entire diabetes population of India.
Diabetes remission score is a useful tool for predicting the remission in patients with type 2 diabetes undergoing IISG or IIDSG. We propose to introduce DRS as a tool to select the type of surgical procedure and to predict the postoperative diabetes remission. Further multicenter studies of patients from various ethnicities are required to confirm our preliminary observations.
We thank all the patients for their participation in the study.
- Greenway SE, Greenway FL 3rd, Klein S: Effects of Obesity Surgery on Non Insulin Dependent Diabetes Mellitus. Arch Surg 2002, 137:1109–1117.View ArticlePubMedGoogle Scholar
- De Paula AL, Macedo AL, Rassi N, Machado CA, Schraibman V, Silva LQ, Halpern A: Laparoscopic Treatment of Type 2 Diabetes Mellitus for Patients with a Body Mass Index less than 35. Surg Endosc 2008, 22:706–716.View ArticleGoogle Scholar
- AL D p, Stival AR, Macedo A, Ribamar J, Mancini M, Halpern A, Vencio S: Prospective Randomized Controlled Trial Comparing 2 Versions of Laparoscopic Ileal Interposition Associated with Sleeve Gastrectomy for Patients with Type 2 Diabetes with BMI 21–34 kg/ m2. Surg Obes Relat Dis 2010, 6:296–305.View ArticleGoogle Scholar
- Tinoco A, El- Kadre L, Tinoco R, Savasi- Rocha P: Short-term and Mid-term Control of Type 2 Diabetes Mellitus by Laparoscopic Sleeve Gastrectomy with Ileal Interposition. World J Surg 2011, 35:2238–2244.View ArticlePubMedGoogle Scholar
- Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM: Who would have thought it? An Operation Proves to be the Most Effective Therapy for Adult-Onset Diabetes Mellitus. Ann Surg 1995, 222:339–350.View ArticlePubMedPubMed CentralGoogle Scholar
- Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248–256.View ArticlePubMedGoogle Scholar
- Dixon JB, Chuang LM, Chong K, Chen SC, Lambert GW, Straznicky NE, Lambert EA, Lee WJ: Predicting the glycemic response to gastric bypass surgery in patients with type 2 Diabetes. Diabetes Care 2013, 36:20–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003, 238:467–484.PubMedPubMed CentralGoogle Scholar
- Dixon JB, O’Brien PE: Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002, 25:358–363.View ArticlePubMedGoogle Scholar
- Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Lee YC: Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg 2012, 16:45–51.View ArticlePubMedGoogle Scholar
- Lee WJ, Chong K, Ser KH, Chen JC, Lee YC, Chen SC, Su YH, Tsai MH: C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg 2012, 22:293–298.View ArticlePubMedGoogle Scholar
- Still CD, Wood GC, Benotti P, Petrick AT, Gabrielsen J, Strodel WE, Ibele A, Seiler J, Irving BA, Celaya MP, Blackstone R, Gerhard GS, Argyropoulos G: Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2014, 2(1):38–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Hari Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, Modi KD: Ileal Transposition with Sleeve Gastrectomy for Control of Type 2 Diabetes. Diabetes Technol Ther 2009, 11:1–5.View ArticleGoogle Scholar
- Kumar Kota S, Ugale S, Gupta N, Naik V, Krishna Kota S, Hari Kumar KVS, Modi KD: Remission of type 2 diabetes mellitus by ileal interposition with sleeve gastrectomy. Int J Endocrinol Metab 2011, 9:374–381.View ArticleGoogle Scholar
- Kota SK, Ugale S, Gupta N, Naik V, Kumar KV, Modi KD: Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian J Endocr Metab 2012, 16:589–598.View ArticleGoogle Scholar
- Kota SK, Ugale S, Gupta N, Modi KD: Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. Diabetes Metab Syndr 2012, 6:125–131.View ArticlePubMedGoogle Scholar
- Kota SK, Ugale S, Gupta N, Krishna S, Modi KD: Ileal Interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. Indian J Endocr Metab 2012, 16:458–459.Google Scholar
- Elariny H, González H, Wang B: Tissue thickness of human stomach measured on excised gastric specimens from obese patients. Surg Technol Int. 2005, 14:119–124.PubMedGoogle Scholar
- Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS: How do we define cure of diabetes? Diabetes Care 2009, 32(11):2133–2135.View ArticlePubMedPubMed CentralGoogle Scholar
- Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E: Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans. J Clin Endocrinol Metab 2001, 86:5083–5086.View ArticlePubMedGoogle Scholar
- Lee WJ, Ser KH, Chong K, Lee YC, Chen SC, Tsou JJ, Chen JC, Chen CM: Laparoscopic sleeve gastrectomy for diabetes treatment in non morbidly obese patients: efficacy and change of insulin secretion. Surgery 2010, 147:664–669.View ArticlePubMedGoogle Scholar
- Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Briatore L, D'Alessandro G, Parodi C, Weiss A, Andraghetti G, Catalano M, Cordera R: The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30–35 kg/m2) and simple overweight (BMI 25–30 kg/m2): a prospective controlled study. Obes Surg 2011, 21:880–888.View ArticlePubMedGoogle Scholar
- Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Fried M, Briatore L, D'Alessandro G, Andraghetti G, Cordera R: Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011, 253:699–703.View ArticlePubMedGoogle Scholar
- Oreopoulos A, Kalantar-Zadeh K, Sharma AM, Fonarow GC: The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med 2009, 25:643–659.View ArticlePubMedGoogle Scholar
- Ramanan B, Gupta PK, Gupta H, Fang X, Forse RA: Development and validation of a bariatric surgery mortality risk calculator. J Am Coll Surg 2012, 214:892–900.View ArticlePubMedGoogle Scholar
- Rubino F, Marescaux J: Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004, 239:1–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798–801.View ArticlePubMedGoogle Scholar
- Kulkarni RN: GIP: no longer the neglected incretin twin? Sci Trans Med 2010, 2:49–47.View ArticleGoogle Scholar
- Hall TC, Pellen MG, Sedman PC, Jain PK: Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg 2010, 20:1245–1250.View ArticlePubMedGoogle Scholar
- Irwin N, Flatt PR: Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009, 52:1724–1731.View ArticlePubMedGoogle Scholar
- Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Köttgen A, Le Bacquer O, et al: Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010, 42:142–148.View ArticlePubMedPubMed CentralGoogle Scholar
- Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Mägi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segrè AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpeläinen TO, et al: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010, 42:937–948.View ArticlePubMedPubMed CentralGoogle Scholar
- Guyenet SJ, Schwartz MW: Clinical Review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab 2012, 97:745–755.View ArticlePubMedPubMed CentralGoogle Scholar
- De Paula AL, Macedo AL, Prudente A, Silva L, Schraibman V, Neto JG: Neuroendocrine Brake for the Treatment of Morbid Obesity: Preliminary Report. Einstei 2005, 3:110–114.Google Scholar
- Pereferrer FS, Gonzàlez MH, Rovira AF, Blasco SB, Rivas AM, del Castillo DD: Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal implications. Obes Surg 2008, 18(1):97–108.View ArticlePubMedGoogle Scholar
- Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced Incretin Effect in Type 2 (noninsulin- dependent) Diabetes. Diabetologia 1986, 29:46–52.View ArticlePubMedGoogle Scholar
- Holst JJ: The Physiology of Glucagon-Like Peptide 1. Physiol Rev 2007, 87:1409–1439.View ArticlePubMedGoogle Scholar
- Kjems LL, Holst JJ, Volund A, Madsbad S: The Influence of GLP-1 on Glucose Stimulated Insulin Secretion: Effects on Beta-Cell Sensitivity in Type 2 and Nondiabetic Subjects. Diabetes 2003, 52:380–386.View ArticlePubMedGoogle Scholar
- Drucker DJ: Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes care 2003, 26:2929–2940.View ArticlePubMedGoogle Scholar
- Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O'harte FP, Flatt PR: Effects of Short-Term Chemical Ablation of the GIP Receptor on Insulin Secretion, Islet Morphology and Glucose Homeostasis in Mice. Biol Chem 2004, 385:845–852.View ArticlePubMedGoogle Scholar
- Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR: Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3) GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes. Diabetes 2005, 54:2436–2446.View ArticlePubMedGoogle Scholar
- Ferrannini E, Cobelli C: The Kinetics of Insulin in Man. General Aspects. Diabetes Metab Rev 1987, 3:335–363.View ArticlePubMedGoogle Scholar
- Vilsboll T, Holst JJ: Incretins, Insulin Secretion and Type 2 Diabetes Mellitus. Diabetologia 2004, 47:357–366.View ArticlePubMedGoogle Scholar
- Aung K, Lorenzo C, Hinojosa MA, Haffner SM: Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014, 99:462–468.View ArticlePubMedPubMed CentralGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.